Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Studied

Randomized comparison of semaglutide with placebo for symptoms, physical limitations and weight in obesity-related heart failure.

Who / model

616 people with obesity, type 2 diabetes and heart failure with preserved ejection fraction, treated for 52 weeks.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Both primary outcomes favored semaglutide: symptom/function scores improved 13.7 versus 6.4 points, and weight fell 9.8% versus 3.4%. For a confirmatory secondary outcome, walking-distance improvement was 14.3 meters greater than with placebo. Serious adverse events occurred in 17.7% versus 28.8%.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary